Recently, it was demonstrated that the same drug slowed down memory decline in a group of patients with obesity and type 2 diabetes (Vadini et al., 2020) and more recently, GLP1 receptor agonists were shown to prevent glucose transport decline through BBB in AD patients, although no conclusions were drawn on cognitive decline (Gejl et al., 2016). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.